Companies ›Financials ›SRTA

SRTA — Nasdaq Insurance

Strata Critical Medical, Inc.

$5,02

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

452,6M USD

P/E

10,9x

EV / Rev

2,0x

Div yield

—

Op margin

-11,3 %

ROE

14,5 %

Net margin

21,0 %

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$5,02

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Strata Critical Medical operates a network for air transport and surgical services for transplant hospitals and Organ Procurement Organizations, providing an integrated solution for donor organ recovery.

Business. Strata Critical Medical, Inc. (SRTA) is a multiline insurance and broker company operating within the insurance industry. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. As segment and geographic breakdowns are not specified, the company is described at the industry level as a provider of insurance and brokerage services.

Classification98 %

SectorFinancials

Business sectorInsurance

ActivityMultiline Insurance & Brokers

Generated · model-assisted

Sell-side consensus

BUY4 analysts

4 buy0 hold0 sell

Avg 12m price target9,25

Analyst recommendations

4 analysts · consensus Buy

Buy4

Hold0

Sell0

12-month price target

9,25

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

4 analysts · indicative

Ownership→

Dimensional Fund Advisors, L.P.

largest disclosed fund holder

Profitability→

14,5 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning SRTA.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials · THIS SECTOR−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to SRTA. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Strata Critical Medical, Inc. (SRTA) is a multiline insurance and broker company operating within the insurance industry. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. As segment and geographic breakdowns are not specified, the company is described at the industry level as a provider of insurance and brokerage services.

Classification98 %

SectorFinancials

Business sectorInsurance

ActivityMultiline Insurance & Brokers

AI synthesis

GENERATED

Strata Critical Medical maintains a conservative capital structure with zero debt-to-equity and a current ratio of 5.93, indicating strong short-term liquidity coverage. The company holds $58.7 million in cash and equivalents against total liabilities of $41.9 million. Despite positive operating cash flow of $3.9 million, free cash flow is negative at -$1.3 million due to $5.2 million in capital expenditures. The market values the company at a price-to-book ratio of 3.0 and an EV/Revenue of 2.0.

Profitability metrics show a return on equity of 14.47% and a return on assets of 12.62%, driven by a net income of $2.2 million on revenue of $67.4 million. However, the company reported an operating loss of -$3.0 million, suggesting that net income is supported by non-operating items or tax benefits rather than core operational efficiency. The gross profit of $14.1 million represents a gross margin of approximately 21%, which is typical for service-intensive logistics businesses but leaves limited room for operating leverage given the current operating loss.

The company’s revenue is derived from its integrated clinical and logistics offerings for transplant centers, hospitals, and Organ Procurement Organizations. There is no segment or geographic breakdown provided in the available data, implying a concentrated business model focused on the US transplant ecosystem. The reliance on contractual relationships with these medical entities creates a specialized but potentially concentrated revenue base.

Growth trajectory analysis is limited by the absence of historical period data in the input. The current quarter’s revenue of $67.4 million serves as the baseline for future projections. The company has recently completed the divestiture of its Passenger business and acquired Keystone, which may impact comparability of historical results and future growth rates.

Risk assessment indicates low liquidity risk but medium dilution risk, with source documents mentioning offering risk. Key operational risks include dependence on third-party aircraft operators, regulatory scrutiny of clinical services, and volatility in aircraft fuel costs. The company also faces risks related to the availability of donor organs and transplant volumes, which are external factors beyond its control.

Recent filing observations highlight the adoption of new FASB accounting standards, including ASU 2025-11 for interim reporting. IR data shows a mean analyst price target of $9.25, significantly above the current market price of $5.02, with a mean recommendation of 1.75 (buy). News events indicate an allocator coverage boost, suggesting increased institutional interest.

Key takeaways

Strong balance sheet with zero debt and a 5.93 current ratio provides financial flexibility.
Operating loss of -$3.0 million contrasts with positive net income, indicating non-operating support.
Medium dilution risk flagged in source documents requires monitoring of share count changes.
Analyst consensus is bullish with a mean price target of $9.25 vs. current price of $5.02.
Business model is highly specialized in organ transport, creating unique regulatory and operational risks.
Recent strategic transactions (divestiture of Passenger business, acquisition of Keystone) may alter future growth dynamics.

Bull / Bear case

Generated · model-assisted

BULL CASE · 4

Net margin of 21% ranks in the top quartile of the insurance cohort, significantly outperforming the 9% median.

The company maintains a low leverage band with a debt-to-equity ratio of 0.17, reducing financial risk.

Strong liquidity is evidenced by a current ratio of 6.38, providing ample buffer against short-term obligations.

Operating losses narrowed from $68 million in FY2023 to $22 million in FY2025, showing improved operational control.

BEAR CASE · 3

Free cash flow deteriorated to -$58.5 million in FY2025, worsening from -$34.5 million in FY2023.

Cash conversion ratio of -1.18 ranks in the bottom quartile, indicating poor ability to generate cash from earnings.

The company faces medium dilution risk, which could negatively impact existing shareholder value and equity stakes.

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2026-03-31

Q4 2025 · Quarter highlights

Revenue $67.4M; Operating income -$3.0M.

Revenue$67.4M

Operating income-$3.0M

Net income$2.2M

Free cash flow-$1.3M

EPS—

Operating cash flow$3.9M

Financials

Income statement

Revenue$67.4M

Gross profit$14.1M

Operating income-$3.0M

Net income$2.2M

Margins

Gross margin21.0%

Operating margin-4.4%

Net margin3.2%

FCF margin-1.9%

Balance sheet

Total assets$327.6M

Total liabilities$41.9M

Total equity$285.7M

Cash & equivalents$58.7M

Long-term debt—

Cash flow

Operating cash flow$3.9M

CapEx$5.2M

Free cash flow-$1.3M

SBC$5.0M

P&L flow · revenue → net income

Highlights

▍Revenue $67.4M
▍Operating income -$3.0M
▍Net margin 3.2%

Valuation FY

Market price

$5,02

Market cap

$452.6M

Enterprise valueⓘ

$393.9M

P/Eⓘ

10.9x

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

2.0x

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

3.0x

P / Tangible bookⓘ

3.0x

Tangible book

$150.8M

Net cashⓘ

$58.7M

Current ratioⓘ

5.9

Debt / equityⓘ

—

ROAⓘ

12.6%

ROEⓘ

14.5%

Cash conversionⓘ

-118.0%

CapEx / revenueⓘ

4.9%

SBC / revenueⓘ

9.0%

Dilution ratioⓘ

—

Revenue by segment

Business relationships

Business relationships5 disclosed relationships · 1 type · extracted from filings & disclosures

Subsidiaries5

EX21:4c9ee78f554aEX21:4c9ee78f554aSubsidiarie97%

EX21:4ebe7a0b09d5EX21:4ebe7a0b09d5Subsidiarie97%

EX21:5db19192dd04EX21:5db19192dd04Subsidiarie97%

EX21:d30e4f264aceEX21:d30e4f264aceSubsidiarie97%

EX21:fbecc158cf25EX21:fbecc158cf25Subsidiarie97%

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

0,07

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-08-03 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	0,07
Revenue	—no estimate	—no estimate	275,7M USD
Operating income	—no estimate	—no estimate	-8,9M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution4 analysts

Strong buy1

Buy3

Hold0

Sell0

Strong sell0

12-month price target$9,25 · Median $8,75

Low $8,00High $11,50

Operating income · consensus-8,9M USD

EPS surprise

+594,4 %

reported vs consensus · beat

Revenue surprise

−28,5 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$8,00

Mean$9,25

Median$8,75

High$11,50

Spot$5,02

+84.3 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskMedium

Liquidity riskLow

Filing-based flags

Source documents mention dilution or offering risk.

Benchmarks vs cohort

Op Margin-11,3 %Bottom quartile

Net Margin21,0 %Above P75

ROE14,5 %Above median

Capex / Rev4,9 %Best in class

D/E0,00Above median

Cash Conv-1,18Bottom quartile

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net disposed 1 854 460 sh1 exercises2 insiders

Krstic Velibor10% owner · Warrants to purchase Class A Common Stock → Class A Common StockDisposed 1 577 500 @ $11,50expire · 2026-05-07
Tomkiel Melissa M.Director, Co-CEO and General Counsel · Stock Option (right to buy) → Class A common stock, $0.0001 par value per shareDisposed 276 960 @ $0,18exercise · 2026-01-02

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Regulatory filings
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data
Reference data

How metrics are computed

Cash Conversion Ratio
operating_cash_flow / net_income
Market Price
input from market-data provider (delayed close or quote-shim mid)
Ev To Revenue
enterprise_value / revenue
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Return On Equity
net_income / total_equity
Market Cap
market_price * shares_outstanding_diluted

Source documents

Strata Critical Medical, Inc. company facts · 2026-08-03
Strata Critical Medical, Inc. 10-Q 2026-05-06 · 2026-08-03
Strata Critical Medical, Inc. 10-K 2026-03-03 · 2026-08-03
Strata Critical Medical, Inc. 10-Q 2025-11-10 · 2026-08-03
Strata Critical Medical, Inc. 10-Q 2025-08-05 · 2026-08-03
allocator_boost (allocator) on SRTA · 2026-08-03
Strata Critical Medical Inc Market data — analyst estimates · 2026-08-03
Strata Critical Medical Inc Market data — ESG · 2026-08-03
Strata Critical Medical, Inc. HA canonical relationships · 2026-08-03

Ownership & reference

Top holders

Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$7M
Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$5M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$5M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$7M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$3M
American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$1M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$14M
Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,00 %$1M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$17M
AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$1M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$2M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$1M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$6M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$1M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$2M
AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$0M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Invesco QQQ TrustFunds · as of 2026-03-310,00 %$0M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

Insider activity

Net selling1 buys · 7 sellsnet -$727K9 insiders · last 365d

Tomkiel Melissa M.Director, Co-CEO and General Counsel · Class A common stock, $0.0001 par value per shareOther 212 309 @ $5,09$1,1M · 2026-07-31
Wunsch Scott MCEO, Logistics · Class A common stock, $0.0001 par value per shareOther 13 992 @ $5,09$71K · 2026-07-31
Heyburn William A.Director, Co-CEO and CFO · Class A common stock, $0.0001 par value per shareOther 199 209 @ $5,09$1,0M · 2026-07-31
Cohen AmirChief Accounting Officer · Class A common stock, $0.0001 par value per shareOther 34 015 @ $5,09$173K · 2026-07-31
Cook William L. IIIDirector · Class A common stock, $0.0001 par value per shareOther 44 438 · 2026-07-30
LAUCK ANDREWDirector · Class A common stock, $0.0001 par value per shareOther 35 260 · 2026-07-30
Wunsch Scott MCEO, Logistics · Class A common stock, $0.0001 par value per shareOther 57 172 · 2026-07-30
Tomkiel Melissa M.Director, Co-CEO and General Counsel · Class A common stock, $0.0001 par value per shareOther 206 953 · 2026-07-30
Heyburn William A.Director, Co-CEO and CFO · Class A common stock, $0.0001 par value per shareOther 181 071 · 2026-07-30
Heyburn William A.Director, Co-CEO and CFO · Class A common stock, $0.0001 par value per shareOther 179 160 · 2026-07-30
Tomkiel Melissa M.Director, Co-CEO and General Counsel · Class A common stock, $0.0001 par value per shareOther 208 929 · 2026-07-30
WIESENTHAL ROBERT SDirector · Class A common stock, $0.0001 par value per shareOther 50 234 · 2026-07-30
Cohen AmirChief Accounting Officer · Class A common stock, $0.0001 par value per shareOther 41 786 · 2026-07-30
Cohen AmirChief Accounting Officer · Class A common stock, $0.0001 par value per shareOther 27 420 · 2026-07-30
PHILIP EDWARD MDirector · Class A common stock, $0.0001 par value per shareOther 30 913 · 2026-07-30
Love ReginaldDirector · Class A common stock, $0.0001 par value per shareOther 37 675 · 2026-07-30
Heyburn William A.Director, Co-CEO and CFO · Class A common stock, $0.0001 par value per shareSold 31 671 @ $5,87$186K · 2026-06-08
Cohen AmirChief Accounting Officer · Class A common stock, $0.0001 par value per shareSold 4 655 @ $5,87$27K · 2026-06-08
Tomkiel Melissa M.Director, Co-CEO and General Counsel · Class A common stock, $0.0001 par value per shareSold 29 730 @ $5,87$175K · 2026-06-08
Wunsch Scott MCEO, Logistics · Class A common stock, $0.0001 par value per shareSold 5 550 @ $5,87$33K · 2026-06-08
Cohen AmirChief Accounting Officer · Class A common stock, $0.0001 par value per shareSold 40 575 @ $5,91$240K · 2026-05-22
Cohen AmirChief Accounting Officer · Class A common stock, $0.0001 par value per shareSold 10 300 @ $5,79$60K · 2026-05-21
Cohen AmirChief Accounting Officer · Class A common stock, $0.0001 par value per shareSold 14 306 @ $5,79$83K · 2026-05-11
Tomkiel Melissa M.Director, Co-CEO and General Counsel · Class A common stock, $0.0001 par value per shareOther 321 750 @ $4,92$1,6M · 2026-04-24
Wunsch Scott MCEO, Logistics · Class A common stock, $0.0001 par value per shareOther 13 922 @ $4,92$68K · 2026-04-24

Short positioning

4.3Mshares short+6.2% vs prior

4.49days to cover

39.5%short of daily vol

859fails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

SRTACanonical

Nasdaq · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskMedium

Liquidity riskLow

Source documents mention dilution or offering risk.

Relationship graph

This companySectorSubsidiaries

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-08-04 00:00 UTCTRANSCRIPTEarnings call — Q3 2026

2026-08-04EVENTUpcomingQ2 2026 earnings (expected) estimated date

2026-07-31INSIDERTomkiel Melissa M. transacted 212.3k sh Class A common stock, $0.0001 par value per share — Director, Co-CEO and General Counsel ~$1.08M

2026-07-31INSIDERWunsch Scott M transacted 14.0k sh Class A common stock, $0.0001 par value per share — CEO, Logistics ~$71k

2026-07-31INSIDERHeyburn William A. transacted 199.2k sh Class A common stock, $0.0001 par value per share — Director, Co-CEO and CFO ~$1.01M

2026-07-31INSIDERCohen Amir transacted 34.0k sh Class A common stock, $0.0001 par value per share — Chief Accounting Officer ~$173k

2026-07-30INSIDERCook William L. III transacted 44.4k sh Class A common stock, $0.0001 par value per share — Director

2026-07-30INSIDERLAUCK ANDREW transacted 35.3k sh Class A common stock, $0.0001 par value per share — Director

2026-07-30INSIDERWunsch Scott M transacted 57.2k sh Class A common stock, $0.0001 par value per share — CEO, Logistics

2026-07-30INSIDERTomkiel Melissa M. transacted 207.0k sh Class A common stock, $0.0001 par value per share — Director, Co-CEO and General Counsel

2026-07-30INSIDERHeyburn William A. transacted 181.1k sh Class A common stock, $0.0001 par value per share — Director, Co-CEO and CFO

2026-07-30INSIDERHeyburn William A. transacted 179.2k sh Class A common stock, $0.0001 par value per share — Director, Co-CEO and CFO

2026-07-30INSIDERTomkiel Melissa M. transacted 208.9k sh Class A common stock, $0.0001 par value per share — Director, Co-CEO and General Counsel

2026-07-30INSIDERWIESENTHAL ROBERT S transacted 50.2k sh Class A common stock, $0.0001 par value per share — Director

2026-07-30INSIDERCohen Amir transacted 41.8k sh Class A common stock, $0.0001 par value per share — Chief Accounting Officer

2026-07-30INSIDERCohen Amir transacted 27.4k sh Class A common stock, $0.0001 par value per share — Chief Accounting Officer

2026-07-30INSIDERPHILIP EDWARD M transacted 30.9k sh Class A common stock, $0.0001 par value per share — Director

2026-07-30INSIDERLove Reginald transacted 37.7k sh Class A common stock, $0.0001 par value per share — Director

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: insider_flow_signal (90d)

2026-06-08 00:00 UTCINSIDER4 insider transactions — 2026-06 · net sell $420k

2026-06-08INSIDERHeyburn William A. sold 31.7k sh Class A common stock, $0.0001 par value per share — Director, Co-CEO and CFO ~$186k

2026-06-08INSIDERCohen Amir sold 4.7k sh Class A common stock, $0.0001 par value per share — Chief Accounting Officer ~$27k

2026-06-08INSIDERTomkiel Melissa M. sold 29.7k sh Class A common stock, $0.0001 par value per share — Director, Co-CEO and General Counsel ~$175k

2026-06-08INSIDERWunsch Scott M sold 5.5k sh Class A common stock, $0.0001 par value per share — CEO, Logistics ~$33k

2026-06-03FILING8-K filing →

2026-05-22 00:00 UTCINSIDER4 insider transactions — 2026-05 · net sell $382k 1 derivative

2026-05-22INSIDERCohen Amir sold 40.6k sh Class A common stock, $0.0001 par value per share — Chief Accounting Officer ~$240k

2026-05-21INSIDERCohen Amir sold 10.3k sh Class A common stock, $0.0001 par value per share — Chief Accounting Officer ~$60k

2026-05-11INSIDERCohen Amir sold 14.3k sh Class A common stock, $0.0001 par value per share — Chief Accounting Officer ~$83k

2026-05-07INSIDERKrstic Velibor disposed of 1.58M sh Warrants to purchase Class A Common Stock — 10% owner

2026-05-06FILING10-Q filing →

2026-05-06FILING8-K filing →

2026-04-24 00:00 UTCINSIDER8 insider transactions — 2026-04 · net sell $3.3M

2026-04-24INSIDERTomkiel Melissa M. transacted 321.8k sh Class A common stock, $0.0001 par value per share — Director, Co-CEO and General Counsel ~$1.58M

2026-04-24INSIDERWunsch Scott M transacted 13.9k sh Class A common stock, $0.0001 par value per share — CEO, Logistics ~$68k

2026-04-14FILINGDEF 14A filing →

2026-03-31EARNINGSQuarterly results — Q4 2025 Revenue USD 67.4M · Net USD 2.2M

2026-03-16 00:00 UTCINSIDER5 insider transactions — 2026-03 · net sell $303k

2026-03-03FILING10-K filing →

Showing the 40 most recent of 58 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread